144 related articles for article (PubMed ID: 16000844)
21. The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.
Sugimoto S; Hotta K; Shimoda T; Imai K; Yamaguchi Y; Nakajima T; Oishi T; Mori K; Takizawa K; Kakushima N; Tanaka M; Kawata N; Matsubayashi H; Ono H
Surg Endosc; 2016 Oct; 30(10):4239-48. PubMed ID: 26718357
[TBL] [Abstract][Full Text] [Related]
22. Low nuclear proliferative activity is associated with nonmetastatic islet cell tumors.
Jorda M; Ghorab Z; Fernandez G; Nassiri M; Hanly A; Nadji M
Arch Pathol Lab Med; 2003 Feb; 127(2):196-9. PubMed ID: 12562234
[TBL] [Abstract][Full Text] [Related]
23. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
[TBL] [Abstract][Full Text] [Related]
24. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors.
Figueiredo FA; Giovannini M; Monges G; Bories E; Pesenti C; Caillol F; Delpero JR
Gastrointest Endosc; 2009 Nov; 70(5):907-14. PubMed ID: 19640525
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
26. Update on pancreatic endocrine tumors.
Frankel WL
Arch Pathol Lab Med; 2006 Jul; 130(7):963-6. PubMed ID: 16831051
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration.
Hosoda W; Takagi T; Mizuno N; Shimizu Y; Sano T; Yamao K; Yatabe Y
Pathol Int; 2010 May; 60(5):358-64. PubMed ID: 20518885
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.
La Rosa S; Adsay V; Albarello L; Asioli S; Casnedi S; Franzi F; Marando A; Notohara K; Sessa F; Vanoli A; Zhang L; Capella C
Am J Surg Pathol; 2012 Dec; 36(12):1782-95. PubMed ID: 23026929
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.
Hochwald SN; Zee S; Conlon KC; Colleoni R; Louie O; Brennan MF; Klimstra DS
J Clin Oncol; 2002 Jun; 20(11):2633-42. PubMed ID: 12039924
[TBL] [Abstract][Full Text] [Related]
30. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.
Rindi G; Azzoni C; La Rosa S; Klersy C; Paolotti D; Rappel S; Stolte M; Capella C; Bordi C; Solcia E
Gastroenterology; 1999 Mar; 116(3):532-42. PubMed ID: 10029611
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
Zhou B; Fang B; Yan S; Wang W
Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
[TBL] [Abstract][Full Text] [Related]
32. Mixed acinar-endocrine carcinoma of the pancreas--a case report.
Cho KJ; Kim JY; Lee SS; Khang SK; Kim CW
J Korean Med Sci; 1996 Apr; 11(2):188-92. PubMed ID: 8835769
[TBL] [Abstract][Full Text] [Related]
33. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
[TBL] [Abstract][Full Text] [Related]
34. CEACAM1 expression in pancreatic endocrine tumors.
Serra S; Asa SL; Bamberger AM; Wagener C; Chetty R
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):286-93. PubMed ID: 19349857
[TBL] [Abstract][Full Text] [Related]
35. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors.
Sipos B; Klapper W; Kruse ML; Kalthoff H; Kerjaschki D; Klöppel G
Am J Pathol; 2004 Oct; 165(4):1187-97. PubMed ID: 15466385
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
37. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.
Zhang L; Lohse CM; Dao LN; Smyrk TC
Hum Pathol; 2011 Mar; 42(3):324-31. PubMed ID: 21190722
[TBL] [Abstract][Full Text] [Related]
38. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors.
Philips P; Kooby DA; Maithel S; Merchant NB; Weber SM; Winslow ER; Ahmad S; Kim HJ; Scoggins CR; McMasters KM; Martin RCG
Pancreas; 2018 Mar; 47(3):326-331. PubMed ID: 29351120
[TBL] [Abstract][Full Text] [Related]
39. Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas.
Scarpa A; Orlandini S; Moore PS; Lemoine NR; Beghelli S; Baron A; Falconi M; Zamboni G
Virchows Arch; 2002 Feb; 440(2):155-159. PubMed ID: 11964045
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
